くすりのしおり

Injection
Published: 9/2020

The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment.
Brand name :
SARCLISA I.V. Infusion 500mg
 Active ingredient:
Isatuximab(genetical recombination)
 Dosage form:
injection
 Print on wrapping:

Effects of this medicine

This medicine binds to human CD38 and inhibits tumor growth by inducing cytotoxic activity, cellular phagocytotic activity and apoptosis.
It is usually used to treat relapse/refractory multiple myeloma.

Before using this medicine, be sure to tell your doctor and pharmacist

  • If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines.
  • If you are pregnant or breastfeeding.
  • If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)

Dosing schedule (How to take this medicine)

  • Your dosing schedule prescribed by your doctor is ((        to be written by a healthcare professional))
  • In general, each treatment cycle is 28 days. For Cycle 1, administer 4 times at an interval of every 1 week (Days 1, 8, 15, and 22). For Cycles 2 and up, administer twice at an interval of every 2 weeks (Days 1 and 15) by intravenous infusion.
  • Consult with the doctor for the treatment duration.
  • You may be administered antihistamines, H2-receptor antagonists and antipyretics before each dose of this medicine to reduce the risk of infusion reactions.

Precautions while taking this medicine

  • Since neutropenia, thrombopenia or anemia may occur with this medicine, periodic blood test should be performed.
  • You should carry your patient ID all the time during treatment and for 6 months after your final dose. If you are ever required to have blood transfusion, you should present your patient ID to the doctor or other health care professionals.
  • If you have a possibility of pregnancy, avoid pregnancy while you are using this medicine and for a certain period after you discontinue this medicine.

Possible adverse reactions to this medicine

The most commonly reported adverse reactions include infusion reactions, upper respiratory infection, pneumonia and diarrhea. If any of these symptoms occur, consult with your doctor or pharmacist.
The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately.
  • respiratory distress, cough, chills [infusion reactions]
  • anemia, prolonged bleeding, malaise [myelosuppression]
  • fever, cough, malaise [infection]
The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.

Storage conditions and other information

For healthcare professional use only : Day Month Year

For further information, talk to your doctor or pharmacist.

Keywords Search

 

 

 

 

Advanced Search

Browse by drug name A-Z
Browse by drug name A-Z